This guidance is intended to describe the Food and Drug Administration's (FDA's) current thinking regarding the scope and application of part 11 of Title 21 of the Code of Federal Regulations; Electronic Records; Electronic Signatures (21 CFR Part 11).
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/39k1e12
No comments:
Post a Comment